GlassScriptPhysician profile
Elizabeth C Brown
NPI 1801848197
$2,781.48
in general payments reported to CMS, 2019-2025
24 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $112 · 2021: $178 · 2022: $11.71 · 2023: $97.74 · 2024: $920 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $384.59 | 2024-2025 | |
| Novo Nordisk INC | $348.43 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $344.93 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Lilly USA, LLC | $288.85 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.50 | 2024-2025 | Xifaxan, Relistor |
| Astrazeneca Pharmaceuticals LP | $228.29 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $212.93 | 2024-2025 | |
| Astellas Pharma US INC | $157.08 | 2024-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $97.74 | 2023 | Quviviq |
| Corcept Therapeutics | $73.15 | 2025 | Korlym |
| Abbott Laboratories | $62.55 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.02 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $43.49 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $37.99 | 2021 | |
| Phathom Pharmaceuticals, INC. | $32.31 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $31.25 | 2024 | |
| Concordia Pharmaceuticals INC. | $27.49 | 2019 | |
| Pfizer INC. | $26.88 | 2025 | |
| Aimmune Therapeutics, INC. | $21.53 | 2025 | Zenpep |
| Exact Sciences Corporation | $16.99 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2024 | |
| Adlon Therapeutics L.P. | $15.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2025 | Jardiance |
| Apria Healthcare LLC | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.